OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Figlin on Ongoing ADAPT Trial for mRCC

July 14th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the ongoing phase III ADAPT trial, which examines AGS-003 combined with sunitinib for the treatment of patients with mRCC.

Dr. Karsh on the TERRAIN Trial for Prostate Cancer

July 13th 2015

Lawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Temel on Anorexia and Cachexia in NSCLC

July 13th 2015

Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.

Dr. Argilés on BRAF-Mutations in Colorectal Cancer

July 10th 2015

Guillem Argilés, MD, department of Medical Oncology, Vall d'Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Dr. Feldman on Link Between Obesity and Risk for RCC

July 9th 2015

Adam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).

Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients

July 8th 2015

Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.

Dr. Vandecaveye on Diffusion MRI for Tumor Differentiation

July 8th 2015

Vincent Vandecaveye, MD, PhD, University Hospitals Leuven, discusses developments of magnetic resonance imaging, specifically diffusion MRI, as a method to differentiate tumors and disease stages.

Dr. Arkenau on Dabrafenib Combined With Trametinib for BRAF-mutated Melanoma

July 7th 2015

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the overall survival results of the COMBI-d study, which examined the combination of dabrafenib and trametinib for the treatment of patients with unresectable or metastatic BRAF V600-mutated melanoma.

Dr. Rosenberg on Complexity of Online Patient Information From NCI Cancer Center Websites

July 6th 2015

Stephen Rosenberg, MD, University of Wisconsin School of Medicine and Public Health, discusses a study examining if online patient information provided by National Cancer Institute (NCI)-designated cancer center websites is too complex for general readership.

Dr. Hall on Multigene Target Panels for Genetic Weaknesses

July 2nd 2015

Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

Dr. Chagpar on the SHAVE Trial for Breast Cancer

July 1st 2015

Anees B. Chagpar, MD, discusses initial results of the SHAVE trial for patients with breast cancer.

Dr. Diefenbach on Ipilimumab/Brentuximab Vedotin in Patients With RR Hodgkin Lymphoma

June 30th 2015

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses a phase I study with an expansion cohort examining the combination of ipilimumab and brentuximab vedotin for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Dr. Saad on Radium-223 in Patients with mCRPC

June 29th 2015

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses the use of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Guarino on IMMU-132 in Advanced Metastatic Lung Cancer

June 26th 2015

Michael J. Guarino, MD, senior staff member, Christiana Care's Department of Medicine, partner, Medical Oncology Hematology Consultants, Christiana Care's Helen F. Graham Cancer Center, discusses initial data from a phase I/ll study examining an anti-ΤROP-2-SN-38 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), as therapy for advanced metastatic lung cancer.

Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

June 25th 2015

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

Dr. Voss on Bevacizumab With CRLX101 in Advanced RCC

June 25th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase II study examining bevacizumab combined with CRLX101 in patients with advanced renal cell carcinoma.

Dr. Leonard on Lenalidomide With Rituximab in Follicular Lymphoma

June 24th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.

Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma

June 23rd 2015

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

Dr. Chanan-Khan Discusses Ibrutinib and BR in CLL

June 23rd 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer Patients

June 23rd 2015

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

NEXT PAGE
PREVIOUS PAGE